Addison Advisors LLC Viracta Therapeutics, Inc. Call Options Transaction History
Addison Advisors LLC
- $336 Million
- Q4 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|---|---|---|---|---|
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
Others Institutions Holding VIRX
# of Institutions
37Shares Held
3.66MCall Options Held
1.8KPut Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.63MShares$81,3120.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA289KShares$14,4580.0% of portfolio
-
Aisling Capital Management LP New York, NY289KShares$14,4280.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny286KShares$14,3190.0% of portfolio
-
Black Rock Inc. New York, NY273KShares$13,6640.0% of portfolio
About Viracta Therapeutics, Inc.
- Ticker VIRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,558,200
- Market Cap $1.88M
- Description
- Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...